10-Q: IN8bio Reports Second Quarter 2024 Financial Results and Provides Business Update

IN8bio, a clinical-stage biopharmaceutical company, released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs and financial position.

Summary

• IN8bio is a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer.
• The company's lead product candidate, INB-400, is in a Phase 2 clinical trial for newly diagnosed glioblastoma (GBM).
• IN8bio also has two programs in Phase 1 clinical trials: INB-200 for newly diagnosed GBM and INB-100 for hematologic malignancies undergoing stem cell transplantation.
• The company's DeltEx platform is yielding preclinical programs like INB-300 and INB-500, targeting AML and other tumors.
• For the six months ended June 30, 2024, IN8bio reported a net loss of $17.2 million, compared to a net loss of $15.2 million for the same period in 2023.
• As of June 30, 2024, the company had cash of $10.2 million, which is expected to fund operations into January 2025.
• The company has an accumulated deficit of $108.4 million as of June 30, 2024.
• IN8bio is exploring additional financing options, including equity and debt offerings, and strategic collaborations.
• The company sold 3,127,331 shares of common stock under its ATM program during the three and six months ended June 30, 2024, resulting in net proceeds of approximately $3.5 million.
• The company may receive an additional $14.8 million in aggregate proceeds if the holders of the Series A warrants exercise their warrants.
• The company may also receive aggregate proceeds of up to $17.7 million from the exercise of its outstanding Series B warrants.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical updates and progress in manufacturing, the financial situation is concerning with a limited cash runway and substantial doubt about the company's ability to continue as a going concern. This creates a cautious outlook from an investment perspective.

Positives

• Clinical data for INB-200 and INB-100 are encouraging, showing promising efficacy and safety profiles.
• The company's DeltEx platform is showing potential for addressing various solid and liquid tumors.
• The company has made progress in manufacturing capabilities, including iPSC-derived gamma-delta T cells.
• The company has received Orphan Drug Designation for INB-400.
• The company has a broad portfolio of preclinical programs.

Negatives

• The company has incurred significant operating losses since inception.
• The company's existing cash is only expected to fund operations into January 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on raising additional capital to fund operations.
• The company has not yet generated any revenue from product sales.
• The company's ability to raise capital may be limited by applicable laws and regulations.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• Raising additional capital may cause dilution to existing stockholders.
• The company's product candidates are in early stages of development and may not be successful.
• Clinical trials may be delayed or unsuccessful.
• The company faces significant competition.
• The company's manufacturing process is complex and may encounter difficulties.
• The company relies on third-party contractors for manufacturing and clinical trials.
• The company is dependent on a single third-party supplier for manufacture of its automated manufacturing device and lentiviral vectors.
• The company's intellectual property may not be adequately protected.
• The company may be subject to product liability claims.
• The company may not be able to obtain regulatory approvals for its product candidates.
• The company may not be able to achieve market acceptance for its product candidates.
• The company may be subject to data privacy and security breaches.
• The company's ability to raise capital may be limited by applicable laws and regulations.
• Unstable market and economic conditions may have serious adverse consequences on the company's business, financial condition and share price.

Future Outlook

The company plans to continue clinical development of INB-400, INB-200, and INB-100, seek potential collaborative partners for earlier stage assets, and file several company-sponsored IND applications over the next few years. The company also plans to submit an IND for the allogeneic arm of INB-400 in 2025 and an IND for a registrational Phase 2 clinical trial for patients with AML undergoing their first allogeneic transplant.

Management Comments

• The company continues to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility.
• The company believes its lofty aspiration of Cancer Zero will one day be achievable, and that it is its responsibility to directly contribute to related global health efforts by pursuing scientific research that will advance cancer treatment.

Industry Context

The company is operating in the competitive field of immuno-oncology, specifically focusing on gamma-delta T cell therapies, which is a relatively new area of research. The company is the most clinically advanced gamma-delta T cell focused cellular therapy company.

Comparison to Industry Standards

• The company's preliminary clinical data for INB-200 showed 92% of evaluable patients exceeding the median progression-free survival of 7 months typically achieved by standard-of-care therapy, which is a positive signal compared to existing treatments.
• The INB-100 data showing 100% of evaluable leukemia patients remaining alive, progression-free, and in durable complete remission through one year is a strong result compared to typical outcomes in this patient population.
• The company's gamma-delta T cell persistence through 365 days is a first for any donor-derived, allogeneic cellular therapy product, which is a significant achievement compared to other cell therapies.
• Competitor data presented at ASCO 2024 demonstrated that persistence of donor derived cells are correlated with levels of HLA matching and they are now advancing their programs to be haploidentical matched as IN8bio has in its INB-100 program.

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises and the possibility of losing their investment if the company cannot continue as a going concern.
• Employees may be affected by potential cost-cutting measures and uncertainty about the company's future.
• Patients may benefit from the development of new therapies, but clinical trials are subject to risks and delays.
• Suppliers and creditors may face uncertainty about the company's ability to meet its obligations.

Next Steps

• The company plans to continue clinical development of INB-400, INB-200, and INB-100.
• The company plans to seek potential collaborative partners for earlier stage assets.
• The company plans to file several company-sponsored IND applications over the next few years.
• The company plans to submit an IND for the allogeneic arm of INB-400 in 2025.
• The company plans to submit an IND for a registrational Phase 2 clinical trial for patients with AML undergoing their first allogeneic transplant.

Key Dates

Keywords

gamma-delta T cells, immunotherapy, glioblastoma, hematologic malignancies, stem cell transplantation, acute myeloid leukemia, clinical trials, biopharmaceutical, DeltEx platform, cell therapy, INB-400, INB-200, INB-100, INB-300, INB-500, iPSC, Orphan Drug Designation